Abiopharma

🔍 Munagala Dinakar (Director)

Company: Blaize Holdings, Inc. (BZAI)

Report Date: 2026-04-17

Detailed Transactions and Holdings:

• Acquired 50,000 shares of Common Stock at $0.57 per share (Direct)
  Date: 2026-04-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 601,422.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 50,000 shares of Common Stock at $2.54 per share (Direct)
  Date: 2026-04-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 551,422.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 50,000 shares of Employee Stock Option (right to purchase) at $0.57 per share (Derivative)
  Date: 2026-04-17 | Code: M | Expires: 2033-09-18 | equity_swap_involved: 0 | shares_owned_after: 4,100,347.00 | transaction_form_type: 4 | Footnotes: F1, F6, F5
• Holds 2,421,971 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-17 | Code: H | shares_owned_after: 2,421,971.00 | Footnotes: F7, F8, F8
• Holds 1,371,303 shares of Earnout Shares (Derivative)
  Date: 2026-04-17 | Code: H | Expires: 2030-01-13 | shares_owned_after: 1,371,303.00 | Footnotes: F9, F9
• Holds 5,755,192 shares of Employee Stock Option (right to purchase) at $1.18 per share (Derivative)
  Date: 2026-04-17 | Code: H | Expires: 2034-10-23 | shares_owned_after: 5,755,192.00 | Footnotes: F10
• Holds 114,650 shares of Employee Stock Option (right to purchase) at $1.29 per share (Derivative)
  Date: 2026-04-17 | Code: H | Expires: 2027-03-15 | shares_owned_after: 114,650.00 | Footnotes: F11
• Holds 176,503 shares of Employee Stock Option (right to purchase) at $14.62 per share (Derivative)
  Date: 2026-04-17 | Code: H | Expires: 2028-11-12 | shares_owned_after: 176,503.00 | Footnotes: F11

Footnotes:

• F1: The reported exercise of 50,000 stock options underlying 50,000 shares of the Issuer's common stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025 (the "10b5-1 trading plan").
• F2: In the reporting person's prior Form 4 filings, earnout shares and unvested restricted stock units had been reported in Table I. These holdings have been moved to Table II, and there have been no transactions in such holdings since the reporting person's last Form 4 filing.
• F3: The reported sales were effected pursuant to the reporting person's Rule 10b5-1 trading plan.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.63, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
• F5: The stock option vests in 36 substantially equal monthly installments beginning on October 19, 2023.
• F6: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of December 22, 2023 and amended on April 22, 2024, October 24, 2024, and November 21, 2024 (the "Merger Agreement") by and among the Issuer (formerly BurTech Acquisition Corp.), BurTech Merger Sub, Inc., Blaize, Inc. ("Legacy Blaize"), and for the limited purposes set forth therein, Burkhan Capital LLC, pursuant to which securities of Legacy Blaize were automatically converted into the right to receive stock options of the Issuer as set forth in the Merger Agreement.
• F7: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• F8: The restricted stock units vest 25% on December 1, 2027, and quarterly thereafter commencing on March 1, 2028.
• F9: On January 13, 2025, the date of the Issuer's business combination, the reporting person received earnout shares in respect of the Issuer's business combination. Each eanout share represents a contingent right to receive one share of the Issuer's common stock if the trading price of the Issuer's common stock exceeds certain thresholds for 20 of 30 consecutive trading days post-closing of the Issuer's business combination.
• F10: The stock option vests as to one third of the underlying shares on July 1, 2025 and thereafter in 24 equal monthly installments.
• F11: The stock option to purchase one share of the Issuer's common stock for each stock option is fully vested and exercisable.